Quick Answer
Equillium, Inc. reported Research And Development Expense of $37.04 million for the year ending 2023.
- Equillium, Inc. showed a decrease of -1.4% in Research And Development Expense from 2022 to 2023.
- This data is from Equillium, Inc.'s annual report (Form 10-K), filed with the SEC on March 25, 2024.
- XBRL data for this metric is available from 2018 to 2023 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2017: $49.9 thousand | Q1 2018: $663.0 thousand | Q2 2018: $540.0 thousand | Q3 2018: $1.22 million | Q1 2019: $3.76 million | Q2 2019: $4.25 million | Q3 2019: $4.18 million | Q1 2020: $4.71 million | Q2 2020: $3.89 million | Q3 2020: $4.22 million | Q1 2021: $5.88 million | Q2 2021: $5.99 million | Q3 2021: $6.97 million.
- Over the full 6 years of available data (2018 to 2023), Equillium, Inc.'s Research And Development Expense has grown by 649.3%.
- Historical annual values: Fiscal year 2023: $37.04 million | Fiscal year 2022: $37.55 million | Fiscal year 2021: $26.38 million | Fiscal year 2020: $19.38 million | Fiscal year 2019: $17.64 million | Fiscal year 2018: $4.94 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: